OBJECTIVES: Pancreatic cystic lesions (PCLs) may be precancerous. Those likely to harbor high-grade dysplasia (HGD) or pancreatic cancer (PC) are targets for surgical resection. Current algorithms to predict advanced neoplasia (HGD/PC) in PCLs lack diagnostic accuracy. In pancreatic tissue and cyst fluid (CF) from PCLs, we sought to identify and validate novel methylated DNA markers (MDMs) that discriminate HGD/PC from low-grade dysplasia (LGD) or no dysplasia (ND). METHODS: From an unbiased whole-methylome discovery approach using predefined selection criteria followed by multistep validation on case (HGD or PC) and control (ND or LGD) tissues, we identified discriminant MDMs. Top candidate MDMs were then assayed by quantitative methylation-specific polymerase chain reaction on archival CF from surgically resected PCLs. RESULTS: Of 25 discriminant MDMs identified in tissue, 13 were selected for validation in 134 CF samples (21 cases [8 HGD, 13 PC], 113 controls [45 ND, 68 LGD]). A tree-based algorithm using 2 CF-MDMs (TBX15, BMP3) achieved sensitivity and specificity above 90%. Discrimination was significantly better by this CF-MDM panel than by mutant KRAS or carcinoembryonic antigen, with areas under the receiver operating characteristic curve of 0.93 (95% confidence interval: 0.86-0.99), 0.71 (0.57-0.85), and 0.72 (0.60-0.84), respectively. Cutoffs for the MDM panel applied to an independent CF validation set (31 cases, 56 controls) yielded similarly high discrimination, areas under the receiver operating characteristic curve = 0.86 (95% confidence interval: 0.77-0.94, P = 0.2). DISCUSSION: Novel MDMs discovered and validated in tissue accurately identify PCLs harboring HGD/PC. A panel of 2 MDMs assayed in CF yielded results with potential to enhance current risk prediction algorithms. Prospective studies are indicated to optimize and further evaluate CF-MDMs for clinical use.
OBJECTIVES:Pancreatic cystic lesions (PCLs) may be precancerous. Those likely to harbor high-grade dysplasia (HGD) or pancreatic cancer (PC) are targets for surgical resection. Current algorithms to predict advanced neoplasia (HGD/PC) in PCLs lack diagnostic accuracy. In pancreatic tissue and cyst fluid (CF) from PCLs, we sought to identify and validate novel methylated DNA markers (MDMs) that discriminate HGD/PC from low-grade dysplasia (LGD) or no dysplasia (ND). METHODS: From an unbiased whole-methylome discovery approach using predefined selection criteria followed by multistep validation on case (HGD or PC) and control (ND or LGD) tissues, we identified discriminant MDMs. Top candidate MDMs were then assayed by quantitative methylation-specific polymerase chain reaction on archival CF from surgically resected PCLs. RESULTS: Of 25 discriminant MDMs identified in tissue, 13 were selected for validation in 134 CF samples (21 cases [8 HGD, 13 PC], 113 controls [45 ND, 68 LGD]). A tree-based algorithm using 2 CF-MDMs (TBX15, BMP3) achieved sensitivity and specificity above 90%. Discrimination was significantly better by this CF-MDM panel than by mutant KRAS or carcinoembryonic antigen, with areas under the receiver operating characteristic curve of 0.93 (95% confidence interval: 0.86-0.99), 0.71 (0.57-0.85), and 0.72 (0.60-0.84), respectively. Cutoffs for the MDM panel applied to an independent CF validation set (31 cases, 56 controls) yielded similarly high discrimination, areas under the receiver operating characteristic curve = 0.86 (95% confidence interval: 0.77-0.94, P = 0.2). DISCUSSION: Novel MDMs discovered and validated in tissue accurately identify PCLs harboring HGD/PC. A panel of 2 MDMs assayed in CF yielded results with potential to enhance current risk prediction algorithms. Prospective studies are indicated to optimize and further evaluate CF-MDMs for clinical use.
Authors: Hongcang Gu; Zachary D Smith; Christoph Bock; Patrick Boyle; Andreas Gnirke; Alexander Meissner Journal: Nat Protoc Date: 2011-03-18 Impact factor: 13.491
Authors: Pavlos Kaimakliotis; Brian Riff; Kamron Pourmand; Vinay Chandrasekhara; Emma E Furth; Evan S Siegelman; Jeffery Drebin; Charles M Vollmer; Michael L Kochman; Gregory G Ginsberg; Nuzhat A Ahmad Journal: Clin Gastroenterol Hepatol Date: 2015-03-25 Impact factor: 11.382
Authors: Bradley W Anderson; Yun-Suhk Suh; Boram Choi; Hyuk-Joon Lee; Tracy C Yab; William R Taylor; Brian A Dukek; Calise K Berger; Xiaoming Cao; Patrick H Foote; Mary E Devens; Lisa A Boardman; John B Kisiel; Douglas W Mahoney; Seth W Slettedahl; Hatim T Allawi; Graham P Lidgard; Thomas C Smyrk; Han-Kwang Yang; David A Ahlquist Journal: Clin Cancer Res Date: 2018-05-29 Impact factor: 12.531
Authors: Mari Mino-Kenudson; Carlos Fernández-del Castillo; Yoshifumi Baba; Nakul P Valsangkar; Andrew S Liss; Maylee Hsu; Camilo Correa-Gallego; Thun Ingkakul; Rocio Perez Johnston; Brian G Turner; Vasiliki Androutsopoulos; Vikram Deshpande; Deborah McGrath; Dushyant V Sahani; William R Brugge; Shuji Ogino; Martha B Pitman; Andrew L Warshaw; Sarah P Thayer Journal: Gut Date: 2011-04-20 Impact factor: 23.059
Authors: Seung-Mo Hong; David Kelly; Margaret Griffith; Noriyuki Omura; Ang Li; Chung-Pin Li; Ralph H Hruban; Michael Goggins Journal: Mod Pathol Date: 2008-09-26 Impact factor: 7.842
Authors: Victoria Gómez; Shounak Majumder; Thomas C Smyrk; Mark D Topazian; Suresh T Chari; Ferga C Gleeson; William S Harmsen; Felicity T Enders; Barham K Abu Dayyeh; Prasad G Iyer; Randall K Pearson; Bret T Petersen; Elizabeth Rajan; Naoki Takahashi; Santhi S Vege; Kenneth K Wang; Michael J Levy Journal: Gastrointest Endosc Date: 2016-04-06 Impact factor: 9.427
Authors: Zhifu Sun; Saurabh Baheti; Sumit Middha; Rahul Kanwar; Yuji Zhang; Xing Li; Andreas S Beutler; Eric Klee; Yan W Asmann; E Aubrey Thompson; Jean-Pierre A Kocher Journal: Bioinformatics Date: 2012-06-10 Impact factor: 6.937
Authors: Paul D Yousefi; Matthew Suderman; Ryan Langdon; Oliver Whitehurst; George Davey Smith; Caroline L Relton Journal: Nat Rev Genet Date: 2022-03-18 Impact factor: 53.242
Authors: Shounak Majumder; William R Taylor; Patrick H Foote; Calise K Berger; Chung Wah Wu; Douglas W Mahoney; William R Bamlet; Kelli N Burger; Neil Postier; Jaime de la Fuente; Karen A Doering; Graham P Lidgard; Hatim T Allawi; Gloria M Petersen; Suresh T Chari; David A Ahlquist; John B Kisiel Journal: Clin Cancer Res Date: 2021-02-16 Impact factor: 13.801
Authors: Ying Liu; Sukhwinder Kaur; Ying Huang; Johannes F Fahrmann; Jo Ann Rinaudo; Samir M Hanash; Surinder K Batra; Aatur D Singhi; Randall E Brand; Anirban Maitra; Brian B Haab Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-06-12 Impact factor: 4.254